Suppr超能文献

线粒体重编程是淋巴恶性肿瘤对 BCL-2 抑制产生耐药的基础。

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; CHU de Clermont-Ferrand, 63000 Clermont-Ferrand, France; Université Clermont Auvergne, EA7453 CHELTER, 63000 Clermont-Ferrand, France.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Harvard Medical School, Boston, MA 02215, USA.

出版信息

Cancer Cell. 2019 Oct 14;36(4):369-384.e13. doi: 10.1016/j.ccell.2019.08.005. Epub 2019 Sep 19.

Abstract

Mitochondrial apoptosis can be effectively targeted in lymphoid malignancies with the FDA-approved B cell lymphoma 2 (BCL-2) inhibitor venetoclax, but resistance to this agent is emerging. We show that venetoclax resistance in chronic lymphocytic leukemia is associated with complex clonal shifts. To identify determinants of resistance, we conducted parallel genome-scale screens of the BCL-2-driven OCI-Ly1 lymphoma cell line after venetoclax exposure along with integrated expression profiling and functional characterization of drug-resistant and engineered cell lines. We identified regulators of lymphoid transcription and cellular energy metabolism as drivers of venetoclax resistance in addition to the known involvement by BCL-2 family members, which were confirmed in patient samples. Our data support the implementation of combinatorial therapy with metabolic modulators to address venetoclax resistance.

摘要

线粒体凋亡可以通过美国食品和药物管理局批准的 B 细胞淋巴瘤 2 (BCL-2) 抑制剂 venetoclax 有效地靶向治疗淋巴恶性肿瘤,但这种药物的耐药性正在出现。我们表明,慢性淋巴细胞白血病对 venetoclax 的耐药性与复杂的克隆转移有关。为了确定耐药性的决定因素,我们在 venetoclax 暴露后,对 BCL-2 驱动的 OCI-Ly1 淋巴瘤细胞系进行了平行的基因组规模筛选,同时对耐药性和工程细胞系进行了整合的表达谱分析和功能特征分析。我们发现,除了已知的 BCL-2 家族成员的参与外,淋巴转录和细胞能量代谢的调节剂也是 venetoclax 耐药性的驱动因素,这在患者样本中得到了证实。我们的数据支持实施联合治疗,包括代谢调节剂,以解决 venetoclax 耐药性。

相似文献

1
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
Cancer Cell. 2019 Oct 14;36(4):369-384.e13. doi: 10.1016/j.ccell.2019.08.005. Epub 2019 Sep 19.
3
Pathways and mechanisms of venetoclax resistance.
Leuk Lymphoma. 2017 Sep;58(9):1-17. doi: 10.1080/10428194.2017.1283032. Epub 2017 Jan 31.
5
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
BMC Cancer. 2017 Jun 2;17(1):399. doi: 10.1186/s12885-017-3383-5.
9
Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
Cancer Discov. 2019 Jul;9(7):890-909. doi: 10.1158/2159-8290.CD-19-0117. Epub 2019 May 2.
10
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Blood. 2021 May 20;137(20):2721-2735. doi: 10.1182/blood.2020010167.

引用本文的文献

2
The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.
Blood Neoplasia. 2025 Apr 25;2(3):100108. doi: 10.1016/j.bneo.2025.100108. eCollection 2025 Aug.
4
ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC.
Nat Chem Biol. 2025 Aug 11. doi: 10.1038/s41589-025-01978-1.
9
Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma.
Blood Neoplasia. 2024 Oct 24;2(1):100050. doi: 10.1016/j.bneo.2024.100050. eCollection 2025 Feb.
10
upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in rearranged lymphomas.
iScience. 2025 May 2;28(6):112584. doi: 10.1016/j.isci.2025.112584. eCollection 2025 Jun 20.

本文引用的文献

2
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.
Cancer Cell. 2018 Nov 12;34(5):724-740.e4. doi: 10.1016/j.ccell.2018.10.005.
3
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.
Nat Med. 2018 Dec;24(12):1859-1866. doi: 10.1038/s41591-018-0233-1. Epub 2018 Nov 12.
5
DeTiN: overcoming tumor-in-normal contamination.
Nat Methods. 2018 Jul;15(7):531-534. doi: 10.1038/s41592-018-0036-9. Epub 2018 Jun 25.
6
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.
8
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Nat Med. 2018 May;24(5):679-690. doi: 10.1038/s41591-018-0016-8. Epub 2018 Apr 30.
9
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.
Nat Commun. 2018 Feb 20;9(1):727. doi: 10.1038/s41467-018-03170-7.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验